Clinical Trial Update: Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the effect of growth hormone on intrahepatic lipid content in patients with nonalcoholic fatty liver disease (NAFLD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• Growth Hormone (somatropin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Status: COMPLETED | Results posted: 2022-11-22